Scholarlink

Purpose <p>To investigate the clinical features of ocular inflammation caused by immune checkpoint inhibitors (ICIs) as immune-related adverse events (irAEs) in Japanese patients.</p> Study design <p>Retrospective observational case series.</p> Methods <p>We reviewed patients with ICI-associated ocular inflammation diagnosed at our institution in 2014–2024. Patient data—background characteristics, primary tumor, causative ICIs, time to onset, laterality, type of inflammation, irAE grade, treatment, visual outcomes, and complications—were analyzed. Stratified analyses were also performed according to the type of ICI.</p> Results <p>The cohort included 7 males and 9 females (mean age, 62.1&#xa0;±&#xa0;14.3&#xa0;years). The most common primary tumor was malignant melanoma (8 patients). The causative ICIs were pembrolizumab, nivolumab, and nivolumab plus ipilimumab (5, 6, and 5 patients, respectively). The median time of onset was 64 days (12–952) post-administration, with significantly earlier onset in patients receiving nivolumab plus ipilimumab. Ocular inflammation was bilateral in 13 patients. Panuveitis (10 patients) was the most common inflammation type, and 6 patients exhibited Vogt–Koyanagi–Harada (VKH) disease–like uveitis. Grade 3 irAEs were the most frequent (11 patients). ICIs were discontinued in 15 patients and 9 required systemic corticosteroids. At the final follow-up, visual acuity had generally improved; however, 4 patients had a best corrected visual acuity of 20/40 or worse due to complications.</p> Conclusion <p>In Japanese patients reviewed at our institution, ICI-associated ocular inflammation often presented as panuveitis, with VKH disease–like uveitis being relatively common. Visual impairment persisted in one-fourth of the patients, emphasizing the importance of careful management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical features and prognosis of immune checkpoint inhibitor-associated ocular inflammation in Japanese patients: a case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Teruki Yamae,
  • Yurika Aoyama,
  • Hidetomo Izawa,
  • Danni Shen,
  • Hotaka Nemoto,
  • Hiroshi Takase,
  • Rie Tanaka

摘要

Purpose

To investigate the clinical features of ocular inflammation caused by immune checkpoint inhibitors (ICIs) as immune-related adverse events (irAEs) in Japanese patients.

Study design

Retrospective observational case series.

Methods

We reviewed patients with ICI-associated ocular inflammation diagnosed at our institution in 2014–2024. Patient data—background characteristics, primary tumor, causative ICIs, time to onset, laterality, type of inflammation, irAE grade, treatment, visual outcomes, and complications—were analyzed. Stratified analyses were also performed according to the type of ICI.

Results

The cohort included 7 males and 9 females (mean age, 62.1 ± 14.3 years). The most common primary tumor was malignant melanoma (8 patients). The causative ICIs were pembrolizumab, nivolumab, and nivolumab plus ipilimumab (5, 6, and 5 patients, respectively). The median time of onset was 64 days (12–952) post-administration, with significantly earlier onset in patients receiving nivolumab plus ipilimumab. Ocular inflammation was bilateral in 13 patients. Panuveitis (10 patients) was the most common inflammation type, and 6 patients exhibited Vogt–Koyanagi–Harada (VKH) disease–like uveitis. Grade 3 irAEs were the most frequent (11 patients). ICIs were discontinued in 15 patients and 9 required systemic corticosteroids. At the final follow-up, visual acuity had generally improved; however, 4 patients had a best corrected visual acuity of 20/40 or worse due to complications.

Conclusion

In Japanese patients reviewed at our institution, ICI-associated ocular inflammation often presented as panuveitis, with VKH disease–like uveitis being relatively common. Visual impairment persisted in one-fourth of the patients, emphasizing the importance of careful management.